Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
RIGL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.50%101.030.0%$1484.62m
BIIBBiogen, Inc. -0.32%243.381.7%$644.21m
AMGNAmgen, Inc. -0.43%222.221.3%$567.12m
GILDGilead Sciences, Inc. -0.37%59.891.0%$536.35m
VRTXVertex Pharmaceuticals, Inc. 1.24%217.871.9%$474.35m
REGNRegeneron Pharmaceuticals, Inc. 0.94%523.612.7%$454.22m
BNTXBioNTech SE 2.34%106.500.0%$445.38m
ILMNIllumina, Inc. 0.35%301.853.5%$377.50m
NVAXNovavax, Inc. 8.59%93.9892.9%$336.34m
EXASEXACT Sciences Corp. 4.61%120.5419.6%$304.90m
MGENMiragen Therapeutics, Inc. 0.35%17.300.7%$272.94m
SRRKScholar Rock Holding Corp. -1.57%41.400.0%$245.77m
APVOAptevo Therapeutics, Inc. -0.18%45.5518.3%$228.01m
SGENSeagen Inc. -3.08%168.075.8%$173.40m
ALXNAlexion Pharmaceuticals, Inc. 1.01%122.612.0%$162.56m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.